Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for rare diseases associated with the PPi-Adenosine Axis. This pathway is crucial for maintaining healthy bones and blood vessels, and disruptions can lead to serious conditions like ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Inozyme's lead product candidate, INZ-701, is an enzyme replacement therapy designed to correct these disruptions by addressing pathologic mineralization and intimal proliferation, targeting the underlying causes of significant morbidity and mortality in these diseases.

Inozyme is committed to restoring health and hope to patients with these rare diseases. The company has assembled a team with decades of expertise in clinical, scientific, regulatory, commercial, and financial areas to drive their mission of developing innovative therapies that transform patient lives. Their focus is on creating novel treatments that provide hope and improve outcomes for those affected by these challenging conditions. Inozyme collaborates with organizations like GACI Global and BeginNGS to enhance disease awareness and support community engagement, underscoring their commitment to early diagnosis and intervention.

Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases associated with the PPi-Adenosine Axis, a critical pathway for maintaining healthy bones and blood vessels. They are focused on addressing the underlying causes of severe conditions like ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, for which there are currently no approved therapies. Inozyme's mission is to bring health and hope to those affected by these rare diseases through the development of effective treatments.

Inozyme Pharma promotes a culture of collaboration, innovation, and dedication to patients. The company values its employees and fosters a supportive and energized work environment where individuals can contribute their expertise and work together towards a common goal of delivering innovative therapies for rare diseases. The company emphasizes its commitment to patient care, research, and development, and its dedication to pushing boundaries and transforming patient lives.

Inozyme Pharma is committed to building a diverse, equitable, and inclusive workplace. The company recognizes the importance of diverse perspectives and experiences in driving innovation and fostering a culture of belonging. Inozyme fosters a welcoming and supportive environment for all employees, regardless of their background, race, ethnicity, gender, sexual orientation, gender identity, or disability. The company actively seeks to recruit, retain, and promote talented individuals from underrepresented groups, and provides training and development opportunities to enhance skills and create a more equitable workplace.